Overview
Ligand Q3 revenue up 123% yr/yr, driven by higher royalty revenue and Pelthos sale
Adjusted EPS for Q3 beats consensus, reflecting strong operational performance
Company raises 2025 revenue guidance to $225 mln-$235 mln, EPS to $7.40-$7.65
Outlook
Ligand raises 2025 revenue guidance to $225 mln - $235 mln
2025 EPS guidance increased to $7.40 - $7.65
Royalties projected at $147 mln - $157 mln for 2025
Result Drivers
ROYALTY REVENUE - 47% increase in royalties driven by Travere Therapeutics' Filspari, Merck/Verona Pharma's Ohtuvayre, and Recordati's Qarziba
STRATEGIC TRANSACTIONS - Revenue boost from Zelsuvmi out-license and Pelthos business sale
FINANCING - Convertible debt financing completed, providing resources for strategic investments
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Adjusted EPS | Beat | $3.09 | $1.93 (7 Analysts) |
Q3 EPS | $5.68 | ||
Q3 Net Income | $117.27 mln | ||
Q3 Basic EPS | $5.99 | ||
Q3 Operating Income | $54.93 mln | ||
Q3 Pretax Profit | $141.14 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Ligand Pharmaceuticals Inc is $180.00, about 5.8% below its November 5 closing price of $190.38
The stock recently traded at 25 times the next 12-month earnings vs. a P/E of 20 three months ago
Press Release: ID:nGNXMcgwf
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)